{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:57:54Z","timestamp":1787497074409,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cjca.2024.02.020","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T11:38:39Z","timestamp":1709293119000},"page":"789-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept"],"prefix":"10.1016","volume":"40","author":[{"given":"Dominic","family":"Chaput","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-0502","authenticated-orcid":false,"given":"Gregor","family":"Andelfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.02.020_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","article-title":"Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry","volume":"164","author":"Wilkinson","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2024.02.020_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1747-0803.2010.00465.x","article-title":"Survival implications: hypertrophic cardiomyopathy in Noonan syndrome","volume":"6","author":"Hickey","year":"2011","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.cjca.2024.02.020_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.hfc.2017.12.005","article-title":"Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies","volume":"14","author":"Calcagni","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cjca.2024.02.020_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2017.07.068","article-title":"Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results","volume":"245","author":"Calcagni","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2024.02.020_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/BF03402039","article-title":"Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype","volume":"8","author":"Abraham","year":"2002","journal-title":"Mol Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.amjcard.2015.06.037","article-title":"Surgical ventricular septal myectomy for patients with Noonan syndrome and symptomatic left ventricular outflow tract obstruction","volume":"116","author":"Poterucha","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2024.02.020_bib8","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.jtcvs.2018.06.040","article-title":"Long-term results of the modified Konno procedure in high-risk children with obstructive hypertrophic cardiomyopathy","volume":"156","author":"Laredo","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2024.02.020_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.semtcvs.2018.12.004","article-title":"Early outcomes of cardiac surgery in patients with Noonan syndrome","volume":"31","author":"Hemmati","year":"2019","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2024.02.020_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.semtcvs.2021.07.027","article-title":"Early outcomes of septal myectomy for obstructive hypertrophic cardiomyopathy in children with Noonan syndrome","volume":"34","author":"Chen","year":"2022","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cjca.2024.02.020_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.xjon.2023.09.032","article-title":"Long-term outcomes of surgery for obstructive hypertrophic cardiomyopathy in a pediatric cohort","volume":"16","author":"Nguyen","year":"2023","journal-title":"JTCVS Open"},{"key":"10.1016\/j.cjca.2024.02.020_bib12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","article-title":"Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition","volume":"73","author":"Andelfinger","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.02.020_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.c.32024","article-title":"New prospectives on treatment opportunities in RASopathies","volume":"190","author":"Gelb","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng1748","article-title":"Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ng1749","article-title":"Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome","volume":"38","author":"Niihori","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib17","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0021-9258(18)53988-0","article-title":"HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy","volume":"268","author":"Thorburn","year":"1993","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2024.02.020_bib18","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.bbamcr.2015.08.006","article-title":"Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy","volume":"1853","author":"Ramos-Kuri","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2024.02.020_bib19","first-page":"109","article-title":"Capacity for resolution of Ras-MAPK-initiated early pathogenic myocardial hypertrophy modeled in mice","volume":"61","author":"Wei","year":"2011","journal-title":"Comp Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ng.2963","article-title":"RAF1 mutations in childhood-onset dilated cardiomyopathy","volume":"46","author":"Dhandapany","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib21","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","author":"Bueno","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.cjca.2024.02.020_bib22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","author":"Harris","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.02.020_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","article-title":"Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth","volume":"108","author":"Kehat","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2024.02.020_bib24","doi-asserted-by":"crossref","first-page":"14074","DOI":"10.1073\/pnas.0610906104","article-title":"Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in\u00a0vivo","volume":"104","author":"Purcell","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2024.02.020_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphar.2015.00149","article-title":"Extracellular signal-regulated kinases 1\/2 as regulators of cardiac hypertrophy","volume":"6","author":"Mutlak","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cjca.2024.02.020_bib26","doi-asserted-by":"crossref","first-page":"16395","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I recapitulates Noonan syndrome in mice","volume":"111","author":"Hernandez-Porras","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2024.02.020_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2024.02.020_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf4766","article-title":"RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy","volume":"9","author":"Cuevas-Navarro","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.cjca.2024.02.020_bib29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI30756","article-title":"Mediating ERK 1\/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome","volume":"117","author":"Nakamura","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2024.02.020_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1172-3-13","article-title":"Leopard syndrome","volume":"3","author":"Sarkozy","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2024.02.020_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/341528","article-title":"Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene","volume":"71","author":"Digilio","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/499925","article-title":"Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease","volume":"78","author":"Tartaglia","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib33","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2024.02.020_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10557-021-07169-z","article-title":"Low-dose dasatinib ameliorates hypertrophic cardiomyopathy in Noonan syndrome with multiple lentigines","volume":"36","author":"Yi","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2024.02.020_bib35","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2024.02.020_bib36","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/annonc\/mdv072","article-title":"A\u00a0randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)","volume":"26","author":"Blumenschein","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2024.02.020_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib38","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2024.02.020_bib39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2024.02.020_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140495","article-title":"KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice","volume":"5","author":"Wong","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.cjca.2024.02.020_bib41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1535-6108(04)00085-6","article-title":"Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects","volume":"5","author":"Tuveson","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cjca.2024.02.020_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2004-11-4207","article-title":"Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells","volume":"106","author":"Schubbert","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2024.02.020_bib43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","article-title":"Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations","volume":"7","author":"Mohi","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cjca.2024.02.020_bib44","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2004-10-4002","article-title":"Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor","volume":"105","author":"Chan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2024.02.020_bib45","doi-asserted-by":"crossref","first-page":"30984","DOI":"10.1074\/jbc.M504699200","article-title":"Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes","volume":"280","author":"Keilhack","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2024.02.020_bib46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cjca.2024.02.020_bib47","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-21-0066","article-title":"Differential outcomes in codon 12\/13 and codon 61 NRAS-mutated cancers in the phase II NCI-MATCH trial of binimetinib in patients with NRAS-mutated tumors","volume":"27","author":"Cleary","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2024.02.020_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cjca.2024.02.020_bib49","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1007\/s00018-016-2297-8","article-title":"Negative feedback regulation of the ERK1\/2 MAPK pathway","volume":"73","author":"Lake","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cjca.2024.02.020_bib50","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2024.02.020_bib51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA approval summary: dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2024.02.020_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104630","article-title":"Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan syndrome","volume":"65","author":"Leegaard","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/genes13010006","article-title":"MEK inhibition in a newborn with RAF1-associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease","volume":"13","author":"Mussa","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.cjca.2024.02.020_bib55","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2023.02.010","article-title":"MEK inhibition improves cardiomyopathy in Costello syndrome","volume":"81","author":"Geddes","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10 suppl 2","key":"10.1016\/j.cjca.2024.02.020_bib56","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.cjca.2022.08.056","article-title":"MAPK and AKT\/MTOR inhibition improves childhood rasopathy-associated cardiomyopathy (abstract)","volume":"38","author":"Andelfinger","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.02.020_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003327","article-title":"Molecular management of multifocal atrial tachycardia in Noonan\u2019s syndrome with MEK1\/2 inhibitor trametinib","volume":"14","author":"Meisner","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib58","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/genes13091503","article-title":"Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with Noonan syndrome and SOS1 mutation","volume":"13","author":"Lioncino","year":"2022","journal-title":"Genes Genes (Basel)"},{"key":"10.1016\/j.cjca.2024.02.020_bib59","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI63034","article-title":"Endothelial ERK signaling controls lymphatic fate specification","volume":"123","author":"Deng","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cjca.2024.02.020_bib60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10456-022-09836-7","article-title":"NRAS(Q61R) mutation in human endothelial cells causes vascular malformations","volume":"25","author":"Boscolo","year":"2022","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cjca.2024.02.020_bib61","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1093\/hmg\/ddu376","article-title":"New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome","volume":"23","author":"Inoue","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155888","article-title":"Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition","volume":"8","author":"Sheppard","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.cjca.2024.02.020_bib63","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0167","article-title":"Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation","volume":"146","author":"Dori","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.cjca.2024.02.020_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.1001105","article-title":"Case report: progressive central conducting lymphatic abnormalities in the RASopathies. Two case reports, including successful treatment by MEK inhibition","volume":"13","author":"Gordon","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.cjca.2024.02.020_bib65","article-title":"Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with Noonan syndrome: case report","volume":"7","author":"Hribernik","year":"2023","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.cjca.2024.02.020_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","article-title":"Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome","volume":"248","author":"Nakano","year":"2022","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2024.02.020_bib67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41591-019-0479-2","article-title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pediatrneurol.2023.08.019","article-title":"Treatment of refractory epilepsy with MEK inhibitor in patients with RASopathy","volume":"148","author":"D\u2019Onofrio","year":"2023","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.cjca.2024.02.020_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.cjca.2024.02.020_bib70","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature12396","article-title":"Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling","volume":"499","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2024.02.020_bib71","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217078","article-title":"RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis","volume":"15","author":"Wong","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2024.02.020_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000991","article-title":"Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene","volume":"6","author":"Sobreira","year":"2010","journal-title":"PLoS Genet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:49:01Z","timestamp":1715680141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0828282X24001855"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.02.020","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}